AGMBAgomAb Therapeutics N.V. American Depositary SharesHealthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $11.41 · now $11.41 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, AGMB has typically landed between $8.20 and $17.23 — a range of −28.1% to +51.0% from the issuance price $11.41.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

132 overlapping 1 month windows · 2026-02-062026-08-17 · basis climatology · forecast (batch).

The cone is anchored at the 2026-09-16 issuance close ($11.41) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where AGMB has typically landed a month from the 2026-09-16 close of $11.41 — the range is history, not a prediction.

$8.2worst · -28.1%$17.23best · +51.0%
  • now $11.41 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $11.54 (+1.2%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $10.23$12.86
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $8.2$17.23
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 132 windows spanning 2026-02-06 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2026-02-27−38.5%−38.5%+1.2%
2026-03-02−35.3%−39.2%+0.0%
2026-02-26−32.2%−32.2%+1.2%
3 best
2026-05-28+54.4%−16.7%+54.4%
2026-06-09+33.5%−1.9%+81.8%
2026-06-12+31.4%+0.0%+85.4%

132 overlapping windows · 2026-02-062026-09-16 · not cherry-picked

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$18$10↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

2 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-09-11Patel NaimishdirectorAward / grant56,32856,328Form 4
2026-09-11Garcia MarinodirectorAward / grant57,48257,482Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.